The American Society of Clinical Oncology has launched an ASCO survey on COVID-19 in Oncology Registry to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes.
The American Association for Cancer Research has split its virtual annual meeting into two sessions, which will be held in April and in June.
FDA has approved the first generic of Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90 mcg/Inhalation, for the treatment or prevention of bronchospasm in patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.
Hospitals have scaled back or closed cancer and blood disease services to make space for patients with COVID-19.
The Community Oncology Alliance board of directors released a position statement opposing the home infusion of chemotherapy, cancer immunotherapy, and cancer treatment supportive drugs because of serious patient safety concerns.
GO2 Foundation for Lung Cancer is working with value-based coalitions to address the concerns of discrimination in access to treatment to make sure that our lung cancer community is not disadvantaged during the COVID-19 crisis.
Researchers from Stanford University's Department of Surgery have created an algorithm that aims to protect operating room team members who perform urgent and emergency operations from COVID-19, and rationally conserve the personal protective equipment they wear.
A global randomized clinical trial for low dose oral Xpovio (selinexor) in hospitalized patients with severe COVID-19 aims to evaluate the drug as a potential treatment option.
GlaxoSmithKline plc. and Vir Biotechnology Inc. are collaborating on research solutions for coronaviruses, including SARS-CoV-2.
Providence Cancer Institute, a part of Providence St. Joseph Health, has launched a phase I study of OncoSec's novel DNA‑encodable, investigational vaccine, CORVax12, designed to act as a prophylactic vaccine to prevent COVID-19.
